Jaguar Health, Inc. (NASDAQ: JAGX)

Sector: Healthcare Industry: Biotechnology CIK: 0001585608
Market Cap 826,424.74
P/B 0.15
P/E -0.02
P/S 0.07
ROIC (Qtr) -86.33
Div Yield % 0.00
Rev 1y % (Qtr) -0.80
Total Debt (Qtr) 31.90 Mn
Debt/Equity (Qtr) 5.67

About

Jaguar Health, Inc., a commercial-stage pharmaceutical company, operates within the healthcare industry, specifically focusing on developing novel, proprietary prescription medicines derived from plants for people and animals with gastrointestinal distress (Jaguar Health, Inc.). The company's primary business activities include the development and commercialization of human prescription pharmaceuticals for essential supportive care and managing neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar Health's operations...

Read more

Price action

Investment thesis

Bull case

  • Operating cash flow of (26.02M) provides exceptional 148.71x coverage of interest expenses (175000), showing strong debt service capability.
  • Operating cash flow of (26.02M) provides exceptional 34.93x coverage of minority interest expenses (745000), showing strong core operations.
  • Tangible assets of 32.19M provide exceptional 54.10x coverage of deferred revenue 595000, showing strong service capability backing.
  • Operating cash flow of (26.02M) fully covers other non-current liabilities (170000) by 153.08x, showing strong long-term stability.
  • Free cash flow of (26.08M) provides exceptional 149.02x coverage of interest expense (175000), showing strong debt service ability.

Bear case

  • Investment activities of (269000) provide weak support for R&D spending of 15.19M, which is -0.02x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Operating cash flow of (26.02M) provides insufficient coverage of deferred revenue obligations of 595000, which is -43.74x, raising concerns about future service delivery capabilities.
  • The company's operating cash flow of (26.02M) shows concerning coverage of stock compensation expenses of 1.09M, with a -23.94 ratio indicating potential earnings quality issues.
  • Free cash flow of (26.08M) provides weak coverage of capital expenditures of 54000, with a -482.93 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (40.47M) show weak coverage of depreciation charges of 2.25M, with a -17.97 ratio indicating high capital intensity and potential reinvestment needs.

Products and Services Breakdown of Revenue (2024)

Consolidation Items Breakdown of Revenue (2024)

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,233.43 Bn -1,338.33 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 458.30 Bn 6,685.60 92.16 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 113.54 Bn 30.89 9.68 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 66.44 Bn -363.26 145.55 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 49.96 Bn 1,146.87 15.56 3.21 Bn
6 ARGX Argenx Se 48.74 Bn 32.36 25,415.62 -
7 BNTC Benitec Biopharma Inc. 40.53 Bn -969.17 0.00 0.00 Bn
8 INSM INSMED Inc 31.37 Bn -26.50 70.18 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.59 11.64
EV to Cash from Ops. EV/CFO -1.12 22.98
EV to Debt EV to Debt 0.91 714.06
EV to EBIT EV/EBIT -0.72 -12.88
EV to EBITDA EV/EBITDA -0.95 6.99
EV to Free Cash Flow [EV/FCF] EV/FCF -1.12 21.89
EV to Market Cap EV to Market Cap 35.27 103.76
EV to Revenue EV/Rev 2.47 196.10
Price to Book Value [P/B] P/B 0.15 21.83
Price to Earnings [P/E] P/E -0.02 -13.53
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) 0.00 -12.07
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.15
Interest Coverage Int. cover (Qtr) 231.25 859.48
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 0.00 -27.11
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -73.42 749.91
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -8.92 -51.60
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -9.67 -4.49
EBIT Growth (1y) % EBIT 1y % (Qtr) -8.92 -61.23
EBT Growth (1y) % EBT 1y % (Qtr) -6.76 -18.17
EPS Growth (1y) % EPS 1y % (Qtr) -109.24 -3.33
FCF Growth (1y) % FCF 1y % (Qtr) 10.10 -32.98
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 15.00 228.66
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.24 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 0.10 3.79
Current Ratio Curr Ratio (Qtr) 0.81 7.24
Debt to Equity Ratio Debt/Equity (Qtr) 5.67 0.42
Interest Cover Ratio Int Coverage (Qtr) 231.25 859.48
Times Interest Earned Times Interest Earned (Qtr) 231.25 859.48
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -324.30 -17,651.95
EBIT Margin % EBIT Margin % (Qtr) -343.39 -18,005.40
EBT Margin % EBT Margin % (Qtr) -341.90 -18,859.43
Gross Margin % Gross Margin % (Qtr) 81.90 -8.65
Net Profit Margin % Net Margin % (Qtr) -341.90 -18,808.76